Author： Langley J.M. Halperin S.A. Smith B.
Publisher： Elsevier
ISSN： 0264-410X
Source： Vaccine, Vol.21, Iss.25, 2003-09, pp. : 3863-3866
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
A phase I/II trial of HIV SF2 gp120/MF59 vaccine in seronegative Thais
By Nitayaphan S. Khamboonruang C. Sirisophana N. Morgan P. Chiu J. Duliege A.-M. Chuenchitra C. Supapongse T. Rungruengthanakit K. deSouza M. Mascola J.R. Boggio K. Ratto-Kim S. Markowitz L.E. Birx D. Suriyanon V. McNeil J.G. Brown A.E. Michael R.A.
Vaccine, Vol. 18, Iss. 15, 2000-02 ,pp. :
Access to resources
Recommend
By da Silva V.O. Borja-Cabrera G.P. Correia Pontes N.N. de Souza E.P. Luz K.G. Palatnik M. Palatnik de Sousa C.B.
Vaccine, Vol. 19, Iss. 9, 2000-12 ,pp. :
Some important issues in the planning of phase III HIV vaccine efficacy trials
By Boily M.-C. Masse B.R. Desai K. Alary M. Anderson R.M.
Vaccine, Vol. 17, Iss. 7, 1999-02 ,pp. :